Cipla, one of India’s leading generic pharmaceutical companies has reportedly acquired the exclusive rights to market skin care products of Percos India. This deal may be worth an estimated Rs 90 crore. The company will market few fast growing brands like Vedaderm, Claz, Actipeel, Tryses and Glycoveda, which have collective sales of around Rs 10 crore.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.75 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1233.60 |
| Zydus Lifesciences | 937.25 |
| Lupin | 2328.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: